Cubist Pharmaceuticals Inc.

Michael W. Bonney has served as our President and Chief Executive Officer and as a member of the Board of Directors since June 2003. From January 2002 to June 2003, he served as our President and Chief Operating Officer. From 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., a biopharmaceutical company, including Vice President, Sales and Marketing from 1999 to 2001. While at Biogen, Mr. Bonney built the commercial infrastructure for the launch of Avonex. Prior to that, Mr. Bonney held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career there serving as National Business Director. Mr. Bonney received a B.A. in Economics from Bates College. Mr. Bonney is a director of NPS Pharmaceuticals, Inc., a biopharmaceutical company, and serves on the Boards of Trustees of the Beth Israel Deaconess Medical Center and Bates College. Mr. Bonney is also a member of the Biotechnology Industry Organization, or BIO, Health Section Governing Body.

David W.J. McGirr, M.B.A. has served as our Senior Vice President and Chief Financial Officer since November 2002. He also served as our Treasurer from November 2002 until January 2003. From 1999 to 2002, Mr. McGirr was the President and Chief Operating Officer of hippo inc, an internet technology, venture-financed company. Mr. McGirr served as a member of hippo's Board of Directors from 1999 to 2003. From 1996 to 1999, he was the President of GAB Robins North America, Inc., a risk management company, serving also as Chief Executive Officer from 1997 to 1999. Mr. McGirr was a private equity investor from 1995 to 1996. From 1978 to 1995, Mr. McGirr served in various positions within the S.G. Warburg Group, ultimately as Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg & Co., Inc., a position held from 1992 to 1995. Mr. McGirr received a B.Sc. in Civil Engineering from the University of Glasgow and received an M.B.A. from The Wharton School at the University of Pennsylvania.

Robert J. Perez, M.B.A. has served as our Executive Vice President and Chief Operating Officer since August 2007. Prior to this, he was our Senior Vice President, Commercial Operations since July 2004. From August 2003 to July 2004 he served as our Senior Vice President, Sales and Marketing. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS Business Unit where he was responsible for leading the U.S. neurology franchise. From 1995 to 2001 he served as a Regional Director, Director of Sales, and Avonex® Commercial Executive at Biogen. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals, ultimately serving as Regional Business Director, responsible for sales, marketing and national accounts for the Western Regional Business Unit. Mr. Perez is a director of AMAG Pharmaceuticals, Inc., a biopharmaceuticals company, and the Biomedical Enterprise Program, a graduate degree program that is jointly administered by the Harvard-MIT Division of Health Sciences and Technology and the MIT Sloan School of Management. Mr. Perez received a B.S. from California State University, Los Angeles and an M.B.A. from The Anderson School at UCLA.

Barry I. Eisenstein, M.D. has served as our Senior Vice President, Scientific Affairs since July 2004. From January 2003 until July 2004 he served as our Senior Vice President, Research and Development. He joined Cubist from ActivBiotics, Inc., where he served as President, Chief Scientific and Medical Officer throughout the year 2002 and as a member of ActivBiotics' Board of Directors from 1997 to 2003. From 1996 to 2002, he was Vice President, Science and Technology at Beth Israel Deaconess Medical Center, responsible for technology transfer, clinical trials and research, research administration and research operations. From 1992 to 1996, Dr. Eisenstein served as Vice President of Eli Lilly and Company's Lilly Research Laboratories and from 1986 to 1992, Dr. Eisenstein was Chairman of the Department of Microbiology and Immunology at The University of Michigan Medical School. He has also held various academic positions and currently serves as Clinical Professor of Medicine at Harvard Medical School and as Editor of the journal, Antimicrobial Agents and Chemotherapy. Dr. Eisenstein received an A.B. from Kenyon College and his M.D. from Columbia University College of Physicians and Surgeons.

Christopher D.T. Guiffre, JD, M.B.A., has served as our Senior Vice President, General Counsel and Secretary since January 2004. He served as our Vice President, General Counsel and Secretary from December 2001 to December 2003. From 1997 to 2001, Mr. Guiffre held various positions of increasing responsibility at Renaissance Worldwide, Inc., a provider of information technology consulting services, including Counsel, Corporate Counsel and Director of Legal Affairs, and Vice President, General Counsel and Clerk. Prior to joining Renaissance Worldwide, he was an Associate at Bingham McCutchen LLP, a national law firm. He received a B.S. from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management. Mr. Guiffre is a member of the Massachusetts Bar.

Lindon M. Fellows has served as our Senior Vice President, Technical Operations since August 2005. From July 2004 until August 2005 Mr. Fellows was Vice President, Corporate Quality Assurance of Millennium Pharmaceuticals, Inc., a biopharmaceutical company, where he was responsible for ensuring product quality and compliance to both U.S. and international requirements. From July 1995 until July 2004, Mr. Fellows held various positions of increasing responsibility at DSM Life Sciences Products, including Managing Director, Director of Quality Compliance, and Vice President of Quality Assurance and Regulatory Affairs with responsibility for anti-infectives, fine chemicals, and food sciences. Mr. Fellows holds a B.S. in Microbiology from Colorado State University.

David S. Mantus, Ph.D. has served as our Vice President, Regulatory Affairs since May 2005. Prior to joining Cubist, Dr. Mantus served as Vice President, Regulatory Affairs at Sention Inc. from 2002-2005, where he was responsible for all regulatory activities, including regulatory strategy, regulatory filings, interactions with regulatory authorities, and corporate compliance with regulations including current Good Manufacturing, Clinical and Laboratory Practices (GMP, GCP, GLP). Prior to Sention Dr. Mantus served various regulatory roles at Shire Biologics, PAREXEL, and Procter and Gamble Pharmaceuticals. In addition to his role at Cubist he is an Adjunct Assistant Professor, Drug Regulatory Affairs at the Massachusetts College of Pharmacy and a Citizen Teacher in the Boston public schools as part of Citizen Schools (www.citizenschool.org). Dr. Mantus co-authored a book on regulatory affairs, "FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics," the second edition of which was published in 2008. He received his Ph.D. in Chemistry from Cornell University and did his post-doctoral research in Biomedical Engineering at the University of Washington.

Dennis D. Keith, Ph.D., has served as Vice President, Chemical Development at Cubist Pharmaceuticals since July 2000. From October 1997 to July 2000, he served as Vice President, Drug Discovery at Cubist. From 1971 to October 1997, Dr. Keith was with Hoffmann-La Roche where he served in various positions, including Director of Antiinfective Chemistry, Senior Director of Medicinal Chemistry and Research Director of Oncology. Dr. Keith received his B.S. in Chemistry from Bates College, Ph.D. in Organic Chemistry from Yale University, and postdoctoral appointment at Harvard with R.B. Woodward.

Gloria A. Vigliani, M.D. has served as our Vice President, Medical Strategy since June 2005. From November 2003 until June 2005, she served as Vice President, Clinical Development. Prior to joining Cubist, Dr. Vigliani was an independent consultant for various companies in drug development and registration. From 1996 to 2002, Dr. Vigliani served in a variety of positions at Biogen Corporation, including Vice President, Medical Research - Immunology/Oncology, Senior Director, Medical Research – Immunology, Director of Clinical Information Management and Surveillance (CIMS), and Director of Drug Safety and Medical Information (DSMI). Prior to her tenure at Biogen, Dr. Vigliani served as Associate Director of Product Safety at Astra USA. Dr. Vigliani is board certified in Internal Medicine and Geriatrics. Prior to joining industry, Dr. Vigliani held the position of Assistant Professor of Medicine at University of Massachusetts Medical School where she practiced general Internal Medicine from 1984-1993. Dr. Vigliani received a B.S. in Biology/Biochemistry from Tufts University and an M.D. from Medical College of Pennsylvania.

Gregory Stea has served as our Senior Vice President, Commercial Operations since February 2009. Prior to this, he served as our Vice President, Sales and Marketing, since September 2007. Previously, Mr. Stea served as Vice President, Sales, from July 2005 to August 2007. From August 2002 to June 2005, he served as our Executive Director, Sales. Prior to joining Cubist, Mr. Stea ran his own business from January 1997 to December 2001. Mr. Stea was employed by Amgen Inc. from May 1988 to December 1996 and was the first person in Amgen's sales organization and a key contributor in building the commercial infrastructure through the launch of Amgen's two flagship products Epogen® and Neupogen® and subsequently became Vice President of Sales in January 1994. Mr. Stea began his pharmaceutical career at Glaxo Pharmaceuticals from 1982 to 1988, where he helped launch several products, including two parenteral cephalosporin antibiotics. Mr. Stea received his B.B.A. from Temple University.

Jeffrey D. Alder, Ph.D. has served as our Vice President, Drug Discovery and Evaluation since August, 2004. Previously, he served as the Senior/Executive Director of Drug Evaluation at Cubist from March 2000 until August 2004. From November 1998 to March 2000, Dr. Alder served as Senior Director, Pharmacology & New Lead Development at Scriptgen Pharmaceuticals, where he was responsible for investigations to evaluate anti-infective and anti-cancer therapeutics. From August 1990 to October 1998, he served as Scientist/Senior Group Leader, Experimental Therapeutics & Pharmacology at Abbott Laboratories where he was responsible for the evaluation of all anti-infective and anti-cancer therapeutics. His Post Doctoral work was at the University of Wisconsin, Medical Microbiology, State Lab of Hygiene. Dr. Alder has authored more than 55 peer-reviewed scientific articles in the area of bacterial, viral, fungal, and cancer therapeutics. He has also evaluated more than 15 different therapeutics that advanced into clinical trials. Dr. Alder received his B.S. and his Ph.D. in Microbiology from The Ohio State University.

Thomas J. Slater has served as our Vice President, Commercial Development & International since May 1999. In 2005 Mr. Slater added responsibility for managing international sales and alliance management through a network of international partners. From July 1998 to April 1999, he served as Senior Vice President of Business Development for Newport Strategies, a pharmaceutical consulting company. From January 1996 to July 1998, he served as Vice President, Pharmaceuticals & Fine Chemicals for Genzyme Corporation, where he was responsible for building a $50 million business in actives drug substances, intermediates, phospholipids and hyaluronic acid products. From 1988 to January 1996, Mr. Slater served in various sales and marketing positions for Genzyme Corporation. Prior to 1988, Mr. Slater served in marketing and sales positions for the pharmaceutical companies Hoffmann-LaRoche and Upjohn. Mr. Slater received his B.S. degree in Biology from Upsala College.

Mr. Singleton has served as one of our directors since June 2003. From 2000 to the present, he has served as Executive Vice President and Chief Financial Officer of CitationShares, LLC, a majority-owned subsidiary of Cessna Aircraft Company and Textron Inc. From 1994 to 1997, Mr. Singleton served as a Managing Director, Executive Vice President and Chief Administrative Officer of CIBC World Markets, an investment banking firm. Previous to that, he served in a variety of roles from 1974 until 1994 at Arthur Andersen & Co., a public accounting firm, ending his tenure there as Partner-In-Charge of the Metro New York Audit and Business Advisory Practice. During 1980 and 1981, he served as a Practice Fellow at the Financial Accounting Standards Board. Mr. Singleton served as a director of Salomon Asset Reinvestment Company from 1998 to 2006. He received an A.B. in Economics from Princeton University and an M.B.A. from New York University. Mr. Singleton is a Certified Public Accountant.

Mr. Bate is President and Chief Executive Officer of NitroMed, Inc. Mr. Bate most recently served as executive vice president at Millennium Pharmaceuticals where, through 2004, his duties included chief financial officer and head of commercial operations. In 1999, he co-founded JSB Partners, an investment banking and transaction advisory firm focused on the biopharmaceutical industry. He was a partner at JSB Partners until 2002. From 1997 to 1999, Mr. Bate served as senior managing director and chief executive officer of MPM Capital, LP, a venture capital company. He was also an advisor to BB Bioventures, a venture capital fund. Mr. Bate's life sciences industry experience also includes six years at Biogen (now Biogen IDEC); from 1993 to 1996 as the company's vice president of sales and marketing, and as chief financial officer from 1990 to 1993. Currently a director of Cubist Pharmaceuticals, Inc. and Coley Pharmaceutical Group, Inc., he is a graduate of Williams College and The Wharton School of the University of Pennsylvania, where he earned an M.B.A.

Dr. Corrigan joined Sepracor in 2003 as Executive Vice President of Research and Development. Prior to joining Sepracor, Dr. Corrigan joined the Upjohn Company in 1993, which became Pharmacia Corp. in 1996. At Pharmacia, Dr. Corrigan served as Group Vice President of Global Clinical Research and Experimental Medicine and in 1998, was promoted to Group Vice President, Global Clinical Research, with responsibility for clinical research, biostatistical/data management and global procurement for compounds in Phases I-IIIB. Prior to joining the pharmaceutical industry with the Upjohn Company, Dr. Corrigan spent several years in academic research at the University of North Carolina Medical School, focusing in psychoneuroendocrinology. During his tenure, Dr. Corrigan was a principal investigator for several novel antipsychotics and continues to maintain an appointment as Adjunct Clinical Professor of Psychiatry. Dr. Corrigan has over twenty years of experience in treating psychiatric and central nervous system disorders and is board certified in psychiatry and neurology. Dr. Corrigan earned his undergraduate and medical degrees from the University of Virginia and subsequently received specialty training in psychiatry at Cornell and Maine Medical Center. Dr. Corrigan serves as a board member of Cubist Pharmaceuticals, Inc. and Neuromed Technologies Inc. and has been elected as a Distinguished Fellow of the American Psychiatric Association (APA).

With more than 30 years of experience in the pharmaceutical industry, Mr. Soeters presently serves as Senior Vice President for Europe for Novo Nordisk, a global healthcare company and worldwide leader in diabetes care. In this position, he is responsible for approximately 2,500 employees and more than $3,2 billion in revenue. Mr. Soeters is of Dutch origin and began his career with Novo Nordisk at the Dutch affiliate. In his 27 years of service to Novo Nordisk, Mr. Soeters has also held the positions of Senior Vice President, International Marketing for Novo Nordisk A/S in Denmark, General Manager of Novo Nordisk affiliates in France and Belgium, and President in the United States and Senior Vice President for North America for Novo Nordisk. He also presently serves on the senior management board of Novo Nordisk A/S and the board of directors of Cubist Pharmaceuticals, Inc.

Dr. Rosenberg has served as one of our directors since March 2005. Since 2003, Dr. Rosenberg has been the Chief Scientific Officer of Promega Corporation, a biotechnology company. From 2001 to 2003, Dr. Rosenberg served as Vice President, Research and Development of Promega Corporation. From 2000 until 2001, Dr. Rosenberg was Senior Vice President, Anti-Infectives, Drug Discovery at GlaxoSmithKline, a pharmaceutical company. From 1996 until 2000, Dr. Rosenberg was Senior Vice President, Anti-Infectives at SmithKline Beecham Corporation, a predecessor company to GlaxoSmithKline. Prior to 2000, Dr. Rosenberg held a variety of roles of increasing responsibility with SmithKline Beecham Corporation. Before joining SmithKline Beecham, Dr. Rosenberg spent 10 years at the National Institutes of Health and was a Section Chief at the National Cancer Institute. Dr. Rosenberg is a director of Promega Corporation, the Medical College of Wisconsin Research Foundation, and Scarab Genomics, a biotechnology company. He also serves as a member of the Advisory Council for the National Institutes of Allergy & Infectious Diseases at the National Institute of Health. He participates on a variety of academic and industry Scientific Advisory Boards and holds an adjunct Professorship at the University of Wisconsin, Department of Bacteriology, Madison, WI. Dr. Rosenberg is an Editor of Microbial Biotechnology, a Senior Editor of the Journal of Bacteriology and a member of several other journal Editorial Boards. Dr. Rosenberg received a B.A. degree from the University of Rochester and a Ph.D. from Purdue University.

Dr. Grégoire has served as one of our directors since June 2006. Since 2007, Dr. Grégoire has served as President, Human Genetic Therapies division of Shire Pharmaceuticals Group plc, a pharmaceuticals company. From August 2005 to June 2008, she served as a director of IDM-Pharma, a biopharmaceuticals company, including serving as Executive Chairwoman from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President and Chief Executive Officer of GlycoFi, Inc., a biotherapeutics company. From 2003 to 2004, Dr. Grégoire was a consultant to the biopharmaceuticals industry. From 2001 through 2003, Dr. Grégoire served as Executive Vice President, Technical Operations, of Biogen, Inc. and its successor Biogen Idec Inc., and from 1995 to 2001, she held various roles of increasing responsibility with Biogen. Prior to Biogen, Dr. Grégoire held clinical research and regulatory roles with Merck & Co., a pharmaceuticals company. She received her Pharm.D. degree from the State University of New York at Buffalo and her pharmacy graduate degree (Bachalaureat en Pharmacie) from the Université Laval, Quebec City.

Mr. Maupay has served as one of our directors since June 1999. Since June 1995, when he retired from Calgon Vestal Laboratories, a division of Bristol Myers Squibb Corporation, Mr. Maupay has served as a director at a number of public and private companies. Mr. Maupay is currently a director of SyntheMed, Inc., a biomaterials company, and is director and non-executive chair of Kensey Nash Corporation, a medical device company. From January 1995 to June 1995, Mr. Maupay served as Group Executive of Calgon Vestal Laboratories. From 1988 to 1995, Mr. Maupay served as President of Calgon Vestal Laboratories, at that time, a subsidiary of Merck and Company. From 1984 to 1988, Mr. Maupay served as Vice President, Healthcare at Calgon Vestal Laboratories. Mr. Maupay received his B.S. in Pharmacy from Temple University and an MBA from Lehigh University.